vs
Amneal Pharmaceuticals, Inc.（AMRX）与Rivian Automotive, Inc.（RIVN）财务数据对比。点击上方公司名可切换其他公司
Rivian Automotive, Inc.的季度营收约是Amneal Pharmaceuticals, Inc.的1.6倍（$1.3B vs $814.3M），Amneal Pharmaceuticals, Inc.净利率更高（4.3% vs -63.1%，领先67.4%），Amneal Pharmaceuticals, Inc.同比增速更快（11.5% vs -25.8%），Amneal Pharmaceuticals, Inc.自由现金流更多（$108.5M vs $-1.1B），过去两年Amneal Pharmaceuticals, Inc.的营收复合增速更高（11.1% vs 3.3%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
Rivian Automotive是2009年成立的美国电动汽车制造商及汽车科技企业，主打基于自研滑板平台打造的电动SUV、皮卡及EDV电动配送货车，旗下R1T皮卡于2021年末正式开启交付，还计划于2023年底前在美国和加拿大布局专属充电网络，其平台可适配新车型也可对外授权使用。
AMRX vs RIVN — 直观对比
营收规模更大
RIVN
是对方的1.6倍
$814.3M
营收增速更快
AMRX
高出37.3%
-25.8%
净利率更高
AMRX
高出67.4%
-63.1%
自由现金流更多
AMRX
多$1.3B
$-1.1B
两年增速更快
AMRX
近两年复合增速
3.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $814.3M | $1.3B |
| 净利润 | $35.1M | $-811.0M |
| 毛利率 | 36.5% | 9.3% |
| 营业利润率 | 13.8% | -64.8% |
| 净利率 | 4.3% | -63.1% |
| 营收同比 | 11.5% | -25.8% |
| 净利润同比 | 212.9% | -9.0% |
| 每股收益（稀释后） | $0.10 | $-0.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXRIVN
| Q4 25 | $814.3M | $1.3B | ||
| Q3 25 | $784.5M | $1.6B | ||
| Q2 25 | $724.5M | $1.3B | ||
| Q1 25 | $695.4M | $1.2B | ||
| Q4 24 | $730.5M | $1.7B | ||
| Q3 24 | $702.5M | $874.0M | ||
| Q2 24 | $701.8M | $1.2B | ||
| Q1 24 | $659.2M | $1.2B |
净利润AMRXRIVN
| Q4 25 | $35.1M | $-811.0M | ||
| Q3 25 | $2.4M | $-1.2B | ||
| Q2 25 | $22.4M | $-1.1B | ||
| Q1 25 | $12.2M | $-545.0M | ||
| Q4 24 | $-31.1M | $-744.0M | ||
| Q3 24 | $-156.0K | $-1.1B | ||
| Q2 24 | $6.0M | $-1.5B | ||
| Q1 24 | $-91.6M | $-1.4B |
毛利率AMRXRIVN
| Q4 25 | 36.5% | 9.3% | ||
| Q3 25 | 34.9% | 1.5% | ||
| Q2 25 | 39.5% | -15.8% | ||
| Q1 25 | 36.8% | 16.6% | ||
| Q4 24 | 36.0% | 9.8% | ||
| Q3 24 | 38.4% | -44.9% | ||
| Q2 24 | 35.6% | -38.9% | ||
| Q1 24 | 36.1% | -43.8% |
营业利润率AMRXRIVN
| Q4 25 | 13.8% | -64.8% | ||
| Q3 25 | 9.0% | -63.1% | ||
| Q2 25 | 15.4% | -85.5% | ||
| Q1 25 | 14.4% | -52.8% | ||
| Q4 24 | 10.4% | -38.1% | ||
| Q3 24 | 12.6% | -133.8% | ||
| Q2 24 | 13.6% | -118.7% | ||
| Q1 24 | -1.6% | -123.3% |
净利率AMRXRIVN
| Q4 25 | 4.3% | -63.1% | ||
| Q3 25 | 0.3% | -75.3% | ||
| Q2 25 | 3.1% | -85.7% | ||
| Q1 25 | 1.8% | -44.0% | ||
| Q4 24 | -4.3% | -42.9% | ||
| Q3 24 | -0.0% | -125.9% | ||
| Q2 24 | 0.9% | -125.8% | ||
| Q1 24 | -13.9% | -120.1% |
每股收益（稀释后）AMRXRIVN
| Q4 25 | $0.10 | $-0.66 | ||
| Q3 25 | $0.01 | $-0.96 | ||
| Q2 25 | $0.07 | $-0.97 | ||
| Q1 25 | $0.04 | $-0.48 | ||
| Q4 24 | $-0.10 | $-0.67 | ||
| Q3 24 | $0.00 | $-1.08 | ||
| Q2 24 | $0.02 | $-1.46 | ||
| Q1 24 | $-0.30 | $-1.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.0M | $6.1B |
| 总债务越低越好 | $2.6B | — |
| 股东权益账面价值 | $-70.8M | $4.6B |
| 总资产 | $3.7B | $14.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMRXRIVN
| Q4 25 | $282.0M | $6.1B | ||
| Q3 25 | $201.2M | $7.1B | ||
| Q2 25 | $71.5M | $7.5B | ||
| Q1 25 | $59.2M | $7.2B | ||
| Q4 24 | $110.6M | $7.7B | ||
| Q3 24 | $74.0M | $6.7B | ||
| Q2 24 | $43.8M | $7.9B | ||
| Q1 24 | $46.5M | $7.9B |
总债务AMRXRIVN
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | $5.5B | ||
| Q1 24 | $2.4B | $4.4B |
股东权益AMRXRIVN
| Q4 25 | $-70.8M | $4.6B | ||
| Q3 25 | $-109.5M | $5.1B | ||
| Q2 25 | $-112.1M | $6.1B | ||
| Q1 25 | $-131.7M | $6.2B | ||
| Q4 24 | $-109.3M | $6.6B | ||
| Q3 24 | $-93.4M | $5.9B | ||
| Q2 24 | $-57.5M | $6.8B | ||
| Q1 24 | $-63.7M | $8.1B |
总资产AMRXRIVN
| Q4 25 | $3.7B | $14.9B | ||
| Q3 25 | $3.6B | $15.2B | ||
| Q2 25 | $3.4B | $15.6B | ||
| Q1 25 | $3.4B | $15.5B | ||
| Q4 24 | $3.5B | $15.4B | ||
| Q3 24 | $3.5B | $14.3B | ||
| Q2 24 | $3.5B | $15.4B | ||
| Q1 24 | $3.5B | $15.7B |
负债/权益比AMRXRIVN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.81× | ||
| Q1 24 | — | 0.55× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $130.3M | $-681.0M |
| 自由现金流经营现金流 - 资本支出 | $108.5M | $-1.1B |
| 自由现金流率自由现金流/营收 | 13.3% | -89.0% |
| 资本支出强度资本支出/营收 | 2.7% | 36.0% |
| 现金转化率经营现金流/净利润 | 3.72× | — |
| 过去12个月自由现金流最近4个季度 | $269.9M | $-2.5B |
8季度趋势，按日历期对齐
经营现金流AMRXRIVN
| Q4 25 | $130.3M | $-681.0M | ||
| Q3 25 | $118.5M | $26.0M | ||
| Q2 25 | $83.8M | $64.0M | ||
| Q1 25 | $7.4M | $-188.0M | ||
| Q4 24 | $118.1M | $1.2B | ||
| Q3 24 | $141.8M | $-876.0M | ||
| Q2 24 | $39.7M | $-754.0M | ||
| Q1 24 | $-4.4M | $-1.3B |
自由现金流AMRXRIVN
| Q4 25 | $108.5M | $-1.1B | ||
| Q3 25 | $106.2M | $-421.0M | ||
| Q2 25 | $61.0M | $-398.0M | ||
| Q1 25 | $-5.8M | $-526.0M | ||
| Q4 24 | $102.9M | $856.0M | ||
| Q3 24 | $124.8M | $-1.2B | ||
| Q2 24 | $29.0M | $-1.0B | ||
| Q1 24 | $-13.6M | $-1.5B |
自由现金流率AMRXRIVN
| Q4 25 | 13.3% | -89.0% | ||
| Q3 25 | 13.5% | -27.0% | ||
| Q2 25 | 8.4% | -30.5% | ||
| Q1 25 | -0.8% | -42.4% | ||
| Q4 24 | 14.1% | 49.4% | ||
| Q3 24 | 17.8% | -131.9% | ||
| Q2 24 | 4.1% | -89.6% | ||
| Q1 24 | -2.1% | -126.5% |
资本支出强度AMRXRIVN
| Q4 25 | 2.7% | 36.0% | ||
| Q3 25 | 1.6% | 28.7% | ||
| Q2 25 | 3.2% | 35.5% | ||
| Q1 25 | 1.9% | 27.3% | ||
| Q4 24 | 2.1% | 18.9% | ||
| Q3 24 | 2.4% | 31.7% | ||
| Q2 24 | 1.5% | 24.4% | ||
| Q1 24 | 1.4% | 21.1% |
现金转化率AMRXRIVN
| Q4 25 | 3.72× | — | ||
| Q3 25 | 50.00× | — | ||
| Q2 25 | 3.74× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 6.62× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
RIVN
| Automotive Segment | $839.0M | 65% |
| Software And Services Segment | $447.0M | 35% |
| Regulatory Credits | $30.0M | 2% |
